Considering the link between EBV replication and XBP1 activation and modulatory effects of S1R agonists in XBP1 and ER stress response, it can be proposed that fluvoxamine might have positive effects in abiding symptoms of COVID-19. This evidence concerns the gene TMBIM4 and COVID-19.